𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia

✍ Scribed by Naseema Gangat; Alexandra P. Wolanskyj; Susan M. Schwager; Ruben A. Mesa; Ayalew Tefferi

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
79 KB
Volume
106
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

There is currently insufficient evidence to either support or refute an association between estrogen‐based hormone treatment (EBHT) and thrombosis risk in essential thrombocythemia (ET).

METHODS

A retrospective review of thrombotic events, which occurred both at diagnosis of ET and during subsequent follow‐up, was performed in a consecutive cohort of women with WHO‐defined ET seen at the Mayo Clinic. Details of EBHT were concomitantly obtained.

RESULTS

A total of 305 women were seen during the study period and followed for a median of 133 months. EBHT at diagnosis was documented in 59 women and such therapy was instituted at a variable time after diagnosis in 34 additional patients. At diagnosis, major thrombosis occurred in 73 patients (24%), including 11 of 59 (19%) on EBHT and 62 of 246 (25%) not on EBHT (P = .28). Thrombosis after diagnosis occurred in 94 patients (31%), including 64 of 212 (30%) not on EBHT, 5 of 17 (29%) in whom EBHT was discontinued at diagnosis, 13 of 42 (31%) in whom EBHT was continued despite the diagnosis of ET, and 12 of 34 (35%) in whom EBHT was started after diagnosis (P = .95). The overall results were the same when arterial and venous events were analyzed separately. However, EBHT in the form of oral contraceptives (OCP) was associated with an increased risk of venous thrombosis (P = .03).

CONCLUSIONS

EBHT is safe in ET outside the setting of OCP use, which might be associated with an increased risk of deep vein thrombosis. Cancer 2006. Β© 2006 American Cancer Society.

πŸ“œ SIMILAR VOLUMES

Leukocytosis at diagnosis and the risk o
Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera
✍ Naseema Gangat; Alexandra P. Wolanskyj; Susan M. Schwager; Curtis A. Hanson; Aya πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 144 KB

## Abstract ## BACKGROUND: Advanced age and a history of thrombosis were well‐established risk factors for thrombosis in essential thrombocythemia (ET) and polycythemia vera (PV); cytoreductive therapy was indicated in their presence. Recent studies have suggested leukocytosis as an additional ris

Leukemogenic risk of hydroxyurea therapy
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
✍ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 417 KB πŸ‘ 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a

Hormone replacement therapy in women wit
Hormone replacement therapy in women with diabetes mellitus: A survey of knowledge of risks and benefits
✍ Davies, PH ;Barnett, AH πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 560 KB

## Abstract Women considering postmenopausal hormone replacement therapy (HRT) require an adequate knowledge base to make an informed choice. To assess knowledge and beliefs about HRT we surveyed 200 consecutive diabetic women in our clinic; 182 completed questionnaires were returned. The age range